Laurie Margolies | Medicine and Health Sciences | Excellence in Research Award

Published on by Research Hypothesis

Dr. Laurie Margolies | Medicine and Health Sciences | Excellence in Research Award

Dr. Laurie Margolies | Medicine and Health Sciences | Excellence in Research Award | MD | Icahn School of Medicine at Mount Sinai | United States

Dr. Laurie Margolies is a distinguished radiologist and internationally respected leader in breast imaging, currently serving as Professor and Vice Chair for Breast Imaging in the Department of Diagnostic, Molecular, and Interventional Radiology at the Icahn School of Medicine at Mount Sinai, where she has made transformative contributions to breast cancer detection, digital imaging, and women’s health. Dr. Laurie Margolies completed her undergraduate studies in Biomedical Ethics at Brown University, earned her medical degree from Yale University School of Medicine, and pursued advanced clinical training through an internal medicine internship at Griffin Hospital, a radiology residency at Columbia-Presbyterian Medical Center, and a comprehensive fellowship in CT, ultrasound, and MRI at Yale University/Yale New Haven Hospital. Her professional experience spans decades of academic appointments, including Instructor at Yale, rising through faculty ranks at Mount Sinai from Assistant Professor to full Professor, while simultaneously serving as System Chief of Breast Imaging across multiple hospitals, Director of Breast Imaging at Mount Sinai Hospital, and Chief of Breast Imaging at the Dubin Breast Center. Dr. Laurie Margolies’s research interests center on breast cancer screening optimization, digital mammography, cardiovascular risk evaluation through mammographic arterial calcifications, health disparity reduction, culturally targeted education programs, imaging physics, AI-driven diagnostic tools, and cross-disciplinary cancer detection methods. Her research skills include expertise in multimodality breast imaging, tomosynthesis assessment, radiologic quality control, population-based screening program development, clinical guideline evaluation, and participation in collaborative research teams across oncology, epidemiology, psychology, and medical physics. She has contributed to impactful studies published in reputable journals such as the Journal of Breast Imaging, Clinical Imaging, Journal of Cancer Education, and PEC Innovation, and she has served on multiple advisory boards for leading medical technology companies, advancing AI-assisted imaging development. Dr. Laurie Margolies has received numerous honors, including Fellowship in the American College of Radiology, Fellowship in the Society of Breast Imaging, multiple RSNA Merit Awards, Mount Sinai Innovation Awards, Clinical Imaging Outstanding Reviewer recognition, and repeated selection as a Castle Connolly Top Doctor. She has served on key institutional committees, leadership panels, and mentoring programs, significantly shaping radiologic quality improvement and cancer screening strategies. Dr. Laurie Margolies continues to influence clinical practice through her dedication to research, patient-centered care, and educational advancement, embodying excellence in academic radiology and demonstrating ongoing potential to elevate global breast imaging standards.

Profile: ORCID | Google Scholar

Featured Publications 

  1. Margolies, L. R., Spear, G. G., Payne, J. I., Iles, S. E., & Abdolell, M. (2025). Artificial intelligence for assessment of digital mammography positioning reveals persistent challenges.

  2. Rossi, J., Cho, L., Newell, M. S., Venta, L. A., Montgomery, G. H., Destounis, S. V., Brem, R. F., Parghi, C., & Margolies, L. R. (2025). Breast arterial calcifications on mammography: A review of the literature.

  3. Mullen, L. A., Ambinder, E. B., Talati, N., & Margolies, L. R. (2023). Mammography information systems: A survey of breast imaging radiologist satisfaction and perspectives.

  4. Head, K. J., Harrington, N. G., Schnur, J. B., Margolies, L., & Montgomery, G. H. (2022). Examining gain- and loss-framed messages in a novel breast cancer screening/cardiovascular context: Does framing matter.

  5. Vang, S., Margolies, L. R., & Jandorf, L. (2022). Screening mammogram adherence in medically underserved women: Does language preference matter.

  6. Fung, J., Vang, S., Margolies, L. R., Li, A., Blondeau-Lecomte, E., Li, A., & Jandorf, L. (2021). Developing a culturally and linguistically targeted breast cancer educational program for a multicultural population.

  7. Margolies, L. R., Salvatore, M., Yip, R., Tam, K., Bertolini, A., Henschke, C., & Yankelevitz, D. (2018). The chest radiologist’s role in invasive breast cancer detection.

 

Denise Faustman | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Denise Faustman | Medicine and Health Sciences | Best Researcher Award

Direcotr of immunobiology laboratory | washington university school of medicine | United States

Dr. Denise Faustman is a physician-scientist whose career exquisitely bridges clinical medicine, immunology, and translational research. She earned her Ph.D. in Molecular and Cellular Biology along with her M.D. in Medicine from Washington University School of Medicine, and she holds a bachelor’s degree in Zoology & Chemistry from the University of Michigan. Over her professional journey, Dr. Faustman has held roles such as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, and she continues to lead efforts in immunotherapy, autoimmunity, and metabolic modulation. Her research interests center on autoimmune disease mechanisms, autoreactive T cells, the immunoregulatory role of TNF/TNFR2, use of Bacillus Calmette–Guérin (BCG) vaccine in type 1 diabetes, epigenetic modulation of immune cells, and the intersection of immunometabolism and regenerative therapies. Her technical and methodological skills span immunology assays (flow cytometry, T-cell functional assays, cytokine profiling), epigenetic and methylation analyses, transcriptomics, metabolomics, clinical trial design, and translational biomarker development. In her career she has authored 115 documents, has accrued 5,972 citations, and holds an h-index of 42, attesting to her sustained academic influence. Professionally, Dr. Faustman has led multiple NIH-funded and translational projects, engaged in global advisory committees (including in immunology, diabetes, and regulatory policy), and established collaborations across institutions in North America and Europe. She has served on scientific advisory boards, chaired expert panels, participated in FDA and NIH review committees, and mentored many early-career scientists. Her honors include recognition for contributions to autoimmune disease research, invitations as plenary or keynote speaker at international conferences, and appointments to leadership roles in professional societies and advisory bodies. In summary, Dr. Denise Faustman combines deep scientific insight, rigorous methodological skill, leadership in translational immunology, and a track record of high-impact publications to make significant contributions both to fundamental immunology and to treatments for type 1 diabetes and other autoimmune diseases. She is well positioned to continue driving innovation in immunotherapy, to mentor the next generation of biomedical scientists, and to lead large-scale international collaborative projects that translate immunological discoveries into patient benefit.

Profile: ORCID | Scopus

Featured Publications

  1. Faustman, D. L. (2001). Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. Journal of Clinical Investigation.

  2. Kodama, S., Kuhtreiber, W., Fujimura, S., Dale, E. A., & Faustman, D. L. (2003). Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science.

  3. Kühtreiber, W. M., Tran, L., Kim, T., Dybala, M., Nguyen, B., Plager, S., Huang, D., Janes, S., Defusco, A., Baum, D., Zheng, H., & Faustman, D. L. (2018). Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations.

  4. Kuhtreiber, W. M., et al. (2023). BCG clinical trial programs in advanced type 1 diabetes.

  5. Faustman, D. L., Davis, M. (2013). TNF receptor 2 and disease: autoimmunity and regenerative medicine.